Literature DB >> 15613443

Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy.

R I Nicholson1, C Staka, F Boyns, I R Hutcheson, J M W Gee.   

Abstract

There is an increasing body of evidence demonstrating that elevated growth signaling in breast cancer cells can promote forms of endocrine resistance in either an estrogen receptor-dependent or -independent manner. The current article reviews what is known about such growth factor signaling networks and resistance to estrogen withdrawal and considers the many novel therapeutic opportunities that stem from this knowledge.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15613443     DOI： 10.1677/erc.1.00778

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


  31 in total

1.  Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells.

Authors:  Chun Chen; William T Baumann; Robert Clarke; John J Tyson
Journal:  FEBS Lett       Date:  2013-08-28       Impact factor: 4.124

Review 2.  Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.

Authors:  Hei Jason Chan; Karineh Petrossian; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-13       Impact factor: 4.292

3.  Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.

Authors:  C Giordano; S Catalano; S Panza; D Vizza; I Barone; D Bonofiglio; L Gelsomino; P Rizza; S A W Fuqua; S Andò
Journal:  Oncogene       Date:  2011-04-18       Impact factor: 9.867

4.  The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells.

Authors:  Lei Wang; Zhao-Yi Wang
Journal:  Oncol Rep       Date:  2010-04       Impact factor: 3.906

Review 5.  Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells.

Authors:  John J Tyson; William T Baumann; Chun Chen; Anael Verdugo; Iman Tavassoly; Yue Wang; Louis M Weiner; Robert Clarke
Journal:  Nat Rev Cancer       Date:  2011-06-16       Impact factor: 60.716

Review 6.  Evolutionary strategy for systemic therapy of metastatic breast cancer: balancing response with suppression of resistance.

Authors:  Yoonseok Kam; Tuhin Das; Susan Minton; Robert A Gatenby
Journal:  Womens Health (Lond)       Date:  2014-07

Review 7.  Effects of psoralens as anti-tumoral agents in breast cancer cells.

Authors:  Maria Luisa Panno; Francesca Giordano
Journal:  World J Clin Oncol       Date:  2014-08-10

8.  Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.

Authors:  Chun Chen; William T Baumann; Jianhua Xing; Lingling Xu; Robert Clarke; John J Tyson
Journal:  J R Soc Interface       Date:  2014-05-07       Impact factor: 4.118

Review 9.  The oestrogen-dependent biology of breast cancer. Sensitivity and resistance to aromatase inhibitors revisited: a molecular perspective.

Authors:  A Urruticoechea
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

10.  Targeting HER2 in breast cancer: overview of long-term experience.

Authors:  Evan Lantz; Ivan Cunningham; Gerald M Higa
Journal:  Int J Womens Health       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.